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Abstract 
Breast cancer is the most common type of cancer in women. The 5-year survival rate in patients with breast cancer 
ranges from 74 to 82 %. Sentinel lymph node biopsy has become an alternative to axillary lymph node dissec-
tion for nodal staging. We evaluated the detection of the sentinel lymph node and metastasis of the lymph node 
using contrast enhanced ultrasonography with Sonazoid. Between December 2013 and May 2014, 32 patients with 
operable breast cancer were enrolled in this study. We evaluated the detection of axillary sentinel lymph nodes and 
the evaluation of axillary lymph nodes metastasis using contrast enhanced computed tomography, color Doppler 
ultrasonography and contrast enhanced ultrasonography with Sonazoid. All the sentinel lymph nodes were identified, 
and the sentinel lymph nodes detected by contrast enhanced ultrasonography with Sonazoid corresponded with 
those detected by computed tomography lymphography and indigo carmine method. The detection of metasta-
sis based on contrast enhanced computed tomography were sensitivity 20.0 %, specificity 88.2 %, PPV 60.0 %, NPV 
55.6 %, accuracy 56.3 %. Based on color Doppler ultrasonography, the results were sensitivity 36.4 %, specificity 95.2 %, 
PPV 80.0 %, NPV 74.1 %, accuracy 75.0 %. Based on contrast enhanced ultrasonography with Sonazoid, the results 
were sensitivity 81.8 %, specificity 95.2 %, PPV 90.0 %, NPV 90.9 %, accuracy 90.6 %. The results suggested that contrast 
enhanced ultrasonography with Sonazoid was the most accurate among the evaluations of these modalities. In the 
future, we believe that our method would take the place of conventional sentinel lymph node biopsy for an axillary 
staging method.
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Background
For nodal staging of breast cancer, sentinel lymph node 
biopsy (SLNB) has become an alternative to axillary 
lymph node dissection (ALND) (Lyman et  al. 2005; 
McCready et al. 2005). If the sentinel lymph node (SLN) 
is free of metastasis, it is not likely that metastatic disease 
is present in the axillary lymph nodes (ALNs); therefore, 
ALND can then be avoided (Dabakuyo et al. 2009).
Generally, SLNB for breast cancer is usually under-
taken using dye and/or radioisotope labeling. However 
these methods have the problem, for example, high 
costs, requirement of a high skill (Yamamoto et al. 2015). 
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Recently, a new method of SLN detection using contrast 
enhanced ultrasonography (CEUS) with Sonazoid was 
reported. The advantages of this method are this CEUS 
with Sonazoid method requires only a ultrasonography 
(US) apparatus and a contrast agent readily available on 
market and does not need radioactive materials (Omoto 
et al. 2009).
Metastatic lymph nodes exhibit peripheral and mixed 
vascularity because of the tumor angiogenesis. Color Dop-
pler US can only provide information regarding the macro 
vessel flow and morphology; therefore, it is difficult to accu-
rately diagnosis lymph node metastasis using this method 
(Yang et  al. 2000). Sonazoid, a new generation contrast 
agent for US, allows for visualization of lymph node micro 
vessels. Compared with previously used imaging modali-
ties, CEUS with Sonazoid would be expected to result in 
more accurate evaluation of lymph node metastasis.
In this study, we evaluated the usefulness of SLNs detec-
tion using CEUS with Sonazoid injected subareolarly and 
the presence of metastasis of SLNs using CEUS by intra-
venous injection of Sonazoid in breast cancer patients.
Results and discussion
Results
CEUS with Sonazoid administering intravenously could 
visualize microvascularities in SLNs. Figure  1 showed 
the representative axillary lymph node images of positive 
metastasis. As shown in the figure, CEUS with Sonazoid 
administering intravenously revealed the multiple vas-
cularity also from other places of hilum. On the other 
hand, Fig.  2 showed the representative images of nega-
tive metastasis. In the images of color Doppler US, there 
seemed to be several vascularities also from other places 
of hilum, but images of CEUS with Sonazoid administer-
ing intravenously revealed that these vasclarities flowed 
from only hilum of this lymph node.
Identification of SLN using CEUS with Sonazoid 
administering subareolarly
All the SLNs were identified by using CEUS with Sona-
zoid administering subareolarly, and these SLNs corre-
sponded with the SLNs detected by CT lymphography 
and indigo carmine method.
Fig. 1 Representative images of a patient with pathologically positive metastasis of axillary lymph node. CECT images showed the non-enhanced 
axillary lymph node (a). CEUS imaging enhanced with Sonazoid revealed that there were the blood flows from multiple micro vessels from the 
other place of hilum (b). Pathological findings showed a metastasis of the axillary lymph node (c, d). White arrow shows the axillary sentinel lymph 
node. White arrow heads show the micro vessel from the other places of hilum
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Evaluation of axillary lymph node metastasis in SLNs 
by using CECT, color Doppler US and CEUS with Sonazoid 
administering intravenously compared with pathological 
findings
The results based on CECT were sensitivity 20.0 %, speci-
ficity 88.2 %, PPV 60.0 %, NPV 55.6 %, accuracy 56.3 %. 
Based on color Doppler US, the results were sensitivity 
36.4 %, specificity 95.2 %, PPV 80.0 %, NPV 74.1 %, accu-
racy 75.0 %. Based on CEUS with Sonazoid administering 
intravenously, the results were sensitivity 81.8  %, speci-
ficity 95.2 %, PPV 90.0 %, NPV 90.9 %, accuracy 90.6 % 
(Table 1). These results showed that CEUS with Sonazoid 
was the most accurate among the evaluations of these 
modalities.
Discussion
Since standard radical mastectomy for the treatment of 
breast cancer was first established by Halsted, surgical 
procedures for breast cancer have continued to improve 
on the basis of the results of randomized clinical trials 
(McCready et al. 2005; Fisher et al. 2002; Jacobson et al. 
1995; Lacour et al. 1983; Maddox et al. 1983; Turner et al. 
1981).
Breast-conserving treatment is now regarded as a 
standard local treatment for early breast cancer. More 
recently, SLNB has become an alternative to ALND for 
nodal staging (Lyman et al. 2005; McCready et al. 2005). 
The SLN hypothesis states that tumor cells that are shed 
from a primary carcinoma migrate through a lymphatic 
channel to a single lymph node before involving further 
lymph nodes within that basin. The SLN is the first lymph 
node that receives lymphatic drainage from a tumor, and 
its identification and analysis for tumor involvement can 
predict the status of the remaining lymph nodes (Kim 
et al. 2006). However, several issues have been reported 
with use of SLNB for nodal staging. First, it was reported 
that the proportion of patients with successfully mapped 
SLNs ranged from 41 to 100  %, with >50  % of studies 
reporting a rate <90  %. The false-negative rate ranged 
from 0 to 29 %, with an average rate of 7.3 % (Kim et al. 
2006). Second, patients may experience local disease 
recurrence following SLNB. Axillary local recurrence 
rates in patients with a negative SLNB and no ALND 
were reported to range from 0 to 1.4 % at 14–46 months 
of follow-up (Naik et al. 2004).
Generally, the combined use of blue dye and isotope is 
recommended for success and accuracy of SLNB (Alber-
tini et al. 1996; Cody et al. 2001; Cox et al. 1998; Noguchi 
et  al. 2000). Goyal et  al. reported that in approximately 
4 % of patients the positive SLN was found by dye alone 
Fig. 2 Representative images of a patient with pathologically negative metastasis of axillary lymph node. CECT images showed moderate-
enhanced axillary lymph node (a). Color Doppler US showed blood flows from multiple micro vessel (b). CEUS imaging with Sonazoid revealed that 
these flows origin from a single vessel in the hilum (c). Pathological findings showed the negative metastasis of this axillary lymph node (d). White 
arrow shows the axillary sentinel lymph node. White arrow heads show the micro vessel from the other places of hilum. Black arrow shows the blood 
flows from a single micro vessel
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and in 3  % by isotope alone; these would have been 
missed by relying on a single technique of localization 
(Goyal et  al. 2006). However, radioisotope method has 
several problems; firstly, the scintigrams cannot clearly 
visualize the direct connection between primary SLNs 
and their afferent lymphatic vessels. Secondly, the radio-
isotope method requires expensive equipment and facili-
ties. Johnson et al. reported that the radioisotope method 
costed $1257.06 for one patient (Johnson et  al. 2011). 
Thirdly, there is what little radiation exposure for both 
patients and medical staffs (Kimura et al. 2013).
For the reasons described above, Dye-only methods 
have been widely performed in the world without nuclear 
medicine departments. This method requires a high level 
of technical skill to trace the dye-stained lymphatic route 
to SLNs. It is, therefore, very important to preoperatively 
detect both true SLNs and the afferent lymphatic route 
from the tumor and areola.
Omoto et  al. reported a SLN detection method using 
CEUS with Sonazoid injected subareolarly in breast 
cancer patients. CEUS with Sonazoid method requires 
only a US apparatus and a contrast agent readily avail-
able on market and does not need radioactive materials. 
The greatest merits of this method are that SLNs can be 
identified without exposing the patient to radioactivity, in 
real-time, with visual images (Omoto et al. 2009). In our 
study, All the SLNs were identified using CEUS method 
with Sonazoid. Moreover, the cost of CEUS with Sona-
zoid method was low, only $162.42 for one patient. These 
results suggested that the combination of CEUS with 
Sonazoid method and blue dye method is useful for the 
detection of SLN and could take the place of the standard 
combination of isotope and blue dye methods.
Axillary lymph node metastasis is a key factor for the 
prognosis of breast cancer and has a major impact on 
decisions regarding treatment modalities; thus, diagnos-
tically accurate methods for determining axillary lymph 
node metastasis are very important to make a correct 
staging for breast cancer patients. Axillary US is widely 
used for the detection of axillary lymph node metastasis 
because it is relatively accurate and noninvasive. Axillary 
US is simple, easy, and less expensive than other modali-
ties. Therefore, it is an elemental test in breast cancer 
evaluation. The sensitivity and specificity of axillary US 
for the detection of axillary lymph node metastasis are 
61.4 and 82.0  %, respectively (Houssami et  al. 2011). In 
spite of presenting a high accuracy in many studies, the 
diagnostic criteria for malignancy and the indication of 
the method remain controversial. The vascularization 
studied at Doppler ultrasonography, basically follows 
two patterns, namely the central pattern, with a single 
hilum vascular signal or dispersed signals distributed 
at the center of the organ, and the peripheral pattern, 
where a linear signal is observed along the peripheral 
zone of the organ. Peripheral vascularization is more 
frequently found in metastatic lymph nodes, while the 
central pattern is more frequently found in the absence 
of malignancy. The importance of the utilization of Dop-
pler ultrasonography as a diagnostic criteria is observed 
as it is associated with other morphological characteris-
tics and not as an isolated criteria (Pinheiro et al. 2014). 
Using color Doppler US increases the information about 
lymph node, but that is limited to the macrovessel vas-
cularity. Contrast-enhanced magnetic resonance imaging 
(cMRI) is generally used to evaluate the regional extent 
of breast cancer before breast-conserving surgery; it ena-
bles the examination of changes in the extent of tumor 
growth pre- and post-chemotherapy, screening of high-
risk patients and those with large breasts, evaluating iso-
lated axillary lymph node metastasis of unknown origin, 
and evaluating axillary lymph node metastasis in breast 
cancer (Ko et al. 2007; Mameri et al. 2008). The sensitiv-
ity and specificity of cMRI for the prediction of axillary 
lymph node metastasis range from 36 to 100 % and 54 to 
100 %, respectively. These ranges are fairly wide because 
they are dependent on the definition of axillary lymph 
Table 1 Comparison of results of axillary lymph node metastasis detection by CT, Doppler US and CEUS with Sonazoid
CECT contrast enhanced computed tomography, US ultrasonography, CEUS contrast enhanced ultrasonography
CECT Color doppler US CEUS with Sonazoid CECT Color doppler US CEUS with Sonazoid
– + – + – +
Pathology
 – 15 2 20 1 20 1
 + 12 3 7 4 2 9
Sensitivity (%) 20 36.4 81.8
Specificity (%) 88.2 95.2 95.2
PPV (%) 60 80 90
NPV (%) 55.6 74.1 90.9
Accuracy (%) 56.3 75 90.6
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node metastasis, the type of contrast agent used, the size 
of the breast tumor, and the number of metastatic axil-
lary lymph nodes (Garcia Fernandez et al. 2011; Harnan 
et al. 2011; Kvistad et al. 2000; Peare et al. 2010; Valente 
et al. 2012). Hwang et al. reported that the actual accu-
racy of cMRI was similar to that of axillary US (Hwang 
et al. 2013). Imaging with fluoro-2-deoxy-d-glucose-pos-
itron emission tomography (PET) is also used to evalu-
ate axillary lymph node metastasis. The fundamental 
strength of PET imaging over conventional imaging is 
its ability to convey functional information that even the 
most exquisitely detailed anatomic image cannot provide. 
However, when surveyed across the multitude of prior 
reports, PET has an overall sensitivity of 88 %, specific-
ity of 92 %, and accuracy of 89 %; however, several of the 
studies achieved higher sensitivity at the expense of lower 
specificity or vice versa. This has led to a wide variation 
in results (Quon and Gambhir 2005).
Sonazoid, a new generation contrast agent for ultra-
sonography, was first manufactured on January 10, 2007 
and is approved for use only in Japan. The active ingre-
dient of Sonazoid is a perflubutane microbubble that is 
stabilized using hydrogenated egg phosphatidyl serine 
sodium, which is a phospholipid. Perflubutane is chemi-
cally stable and insoluble in water. Therefore, it has a long 
lifespan in the body because it hardly dissolves in the 
blood. CEUS with Sonazoid administering intravenously 
for liver tumors has come to be frequently performed 
in Japan. Aoki et al. suggested that CEUS with Sonazoid 
administering intravenously is useful in distinguishing 
tumor-induced and inflammation-induced lymph node 
enlargement (Omoto et al. 2009; Aoki et al. 2011).
CEUS with Sonazoid administering intravenously can 
also allow for the visualization of microvessels. Color 
Doppler US provides information about macrovessel 
flow and morphology and can evaluate palpable lymph 
nodes more accurately than axillary US; however, it can-
not be used to evaluate microvessels and is therefore not 
applicable to the evaluation of nonpalpable nodes (Yang 
et  al. 2000). We reported a breast cancer patient after 
SLNB whose lymph node swelling was diagnosed as no 
metastasis accurately using CEUS with Sonazoid admin-
istering intravenously (Matsuzawa et  al. 2015). One of 
the advantage of CEUS with Sonazoid administering 
intravenously is that the operators can get clear imagina-
tion of the placement, depth and characteristics by per-
forming this by themselves. Li et  al. reported that it is 
important to check blood vessel volume and density for 
evaluation of lymph node metastasis in vivo system (Li 
et al. 2013).
There were three misdiagnosed cases by using CEUS 
with Sonazoid administering intravenously those 
included; one false positive case and two false nega-
tive cases (Table 2). In false positive case No. 1, multiple 
microvessels were visualized by using CEUS with Sona-
zoid administering intravenously. However, the patholog-
ical findings revealed that there was the flow from only 
hilum and negative metastasis. In false negative case No. 
1, the blood flow from only hilum was detected by CEUS 
with Sonazoid administering intravenously, but the result 
of pathological findings revealed the micro invasion 
less than 1 mm. In false negative case No. 2, it was dif-
ficult to visualize the hilum in itself. These problems will 
be solved by improvement of the ultrasound apparatus, 
accumulation of cases and our knowledge for the imaging 
features of SLNs of positive or negative metastasis. In the 
present study, CEUS with Sonazoid administering intra-
venously was the most accurate evaluation compared 
with other modalities. By overcoming these problems 
described above, we propose that the combination of 
CEUS with Sonazoid administering both subareolarly 
and intravenously can result in an accurate diagnosis of 
axillary lymph node metastasis.
Methods
Patients
This study was approved by the Bioethics Committee of 
Hokkaido social work association Obihiro Hospital. The 
clinical study protocol was explained in detail to patients 
eligible for the study. If a patient agreed to participate, 
she would then sign an informed consent form and was 
registered for the study.
Table 2 Clinical and  pathological characteristics of  misdiagnosed cases by  using CEUS with  Sonazoid administering 
intravenously







False positive case 
no. 1
40 BCS + SLNB pT1c N0 IA MUC Positive metastasis Negative metastasis Multiple microves-
sels
False negative case 
no. 1
51 MRM + SLNB + Ax pT1c N1mi IB IDC Negative metas-
tasis
Positive metastasis Detection of flow 
from only hilum
False negative case 
no. 2
77 MRM + SLNB + Ax pT2 N1 IIIIA IDC Negative metas-
tasis
Positive metastasis Difficulty of visualiza-
tion of hilum
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Between December 2013 and May 2014, 32 female 
patients (median age 60.4  years, range 32–86  years) with 
histologically diagnosed as breast cancer by US guided 
core needle biopsy. It was confirmed that they did not 
have distant metastases by contrast enhanced computed 
tomography (CECT) findings. The clinical and pathological 
characteristics are shown in Table 3. The patients included 
6 cases (18.6 %) in pTis stage, 5 cases (15.6 %) in pT1b stage, 
9 cases (28.1  %) in pT1c stage, 3 cases (9.4  %) in ypT1c 
stage, 7 cases (21.9 %) in pT2 stage and 2 cases (6.4 %) in 
ypT2 stage. The patients included 21 cases (65.6 %) in pN0 
stage, 1 cases (3.1 %) in pN1mi stage and 10 cases (31.3 %) 
in pN1 stage. 9 cases (28.1 %) of patients were performed 
breast conserving surgery and 23 cases (71.9 %) of patients 
were performed modified radical mastectomy. 19 cases 
(59.4 %) of patients were performed SLNB and no metas-
tasis in SLN, but 9 cases (28.1 %) of patients were positive 
SLN metastasis so underwent axillary dissection in addi-
tion. Four cases (12.5  %) of patients were considered to 
have positive metastasis in the axillary lymph nodes so they 
underwent axillary dissection from the beginning.
Imaging examinations
All patients underwent CECT for the evaluations of sys-
temic metastasis including ALNs before admission.
In the morning on the day before the operation, at 
first the patients underwent conventional US (including 
B-mode and color Doppler) for re-check the metastasis 
of ALNs. Next, injections of 1 ml of Sonazoid were gently 
administered using a plastic syringe with a 22G-needle 
into subareolar region. The transducer was placed lightly 
on the skin and the area from the outside of the upper 
lateral quadrant area to the axillary region was observed 
by US. The long axial view was scanned parallel to a line 
connecting the nipple and the axilla. The ultrasound 
equipment used in this study was an Aplio500 (Toshiba 
medical systems, Tokyo, Japan). Contrast enhanced scan-
ning was performed using coded-phase inversion har-
monic US with mechanical indices (MIs) of 0.15–0.19, 
of 10–20  mm from the surface (Fig.  3). We marked the 
skin directly above the detected SLN. In the evening 
on the same day, the patients underwent CEUS by an 
administration intravenously with Sonazoid (0.015 ml/kg 
body weight). If the contrast-enhancement of SLNs was 
remained before intravenous injection, we pointed the 
ultrasound beam to the SLNs for destroying the bubble of 
Sonazoid using conventional B-mode scan with high MI 
until the disappearance of the enhancement. We used the 
same Aplio500 as the SLN detection for this examination.
After the CEUS with Sonazoid injected subareolarly, 
the patients underwent CT lymphography for the detec-
tion of SLNs. CT lymphography was performed using 
a 64-detector row CT scanner (Toshiba, Aquilion 64, 
Table 3 Clinical and  pathological characteristics of  33 
patients with breast cancer
BCS breast conserving surgery, MRM modified radical mastectomy, SLNB sentinel 
lymph node biopsy, AD axillary dissection, IDC invasive ductal carcinoma, 
DCIS ductal carcinoma in situ, MUC mucinous carcinoma, SCC squamous cell 
carcinoma
No. of patients Percentage
Age (years) 60.4 ± 13.2 (range 32–86)
Palpability
 Breast tumor
  Yes 22 68.8
  No 10 31.2
 ALN
  Yes 2 6.3
  No 30 93.7
Surgery
 Breast
  BCS 9 28.1
  MRM 23 71.9
 Axilla
  SLNB 19 59.4
  SLNB + AD 9 28.1
  AD 4 12.5
Laterality
 Right 11 34.4
 Left 21 65.6
Tumor size (mm) 21.9 ± 19.2 (6–115)
Multiplicity
 Yes 4 12.5
 No 28 87.5
T stage
 pTis 6 18.6
 pT1a 0 0
 pT1b 5 15.6
 pT1c 9 28.1
 ypT1c 3 9.4
 pT2 7 21.9
 ypT2 2 6.4
N stage
 0 21 65.6
 1mi 1 3.1
 1 10 31.3
Stage
 0 6 18.8
 IA 11 34.4
 IB 1 3.1
 IIA 7 21.9
 IIB 3 9.4
 IIIA 4 1.3
Histology
 IDC 23 71.9
 DCIS 5 15.6
 MUC 3 9.4
 SCC 1 3.1
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Japan). Under local anesthesia, 3  ml of undiluted iopa-
midol (Iopamiron 370; Bayer, Osaka, Japan) was injected 
into the periareolar areas followed by gentle massage for 
60 s. Each patient was placed in the supine position with 
arms positioned in a cranial direction. We marked the 
skin directly above the detected SLN using another color.
In the operation while patients were under general 
anesthesia, a 5 ml of indigo carmine blue dye was injected 
into the periareolar areas, followed by 1 min of massage 
to promote lymphatic flow. An incision (2–3  cm) was 
made along the skin surface corresponding to the marks 
that had been made during CEUS with Sonazoid admin-
istering subareolarly and CT lymphography. Then SLNs 
were identified and biopsied during breast-conserving 
surgery. In case involving mastectomy, we attempted to 
identify SLNs after making a skin flap. We tried to detect 
SLNs by following the lymphatic route dyed by indigo 
carmine. The entirety of the SLN was cut along the lon-
gitudinal axis into sections of 2.0 mm thickness. When a 
positive SLN was found in a frozen section, total axillary 
lymph node dissection (ALND) was performed.
Identification of SLNs by CEUS with Sonazoid injected 
subareolarly
We compared the location which was detected preop-
eratively by CEUS with Sonazoid administering subare-
olarly and CT lymphography with the location that was 
detected intraoperatively by indigo carmine method. The 
correspondence ratio between these data was analyzed.
Evaluation of axillary lymph node metastasis in SLNs 
by using CECT
Metastatic lymph nodes were evaluated independently 
by two breast surgeon (F.M., T.E.) who did not know 
the clinical outcome based on the short-axis diameter 
(>5  mm), internal fat density indicating absence of a 
central image, and early strong enhancement, compared 
with the late phase of the ALNs on CT images.
Evaluation of axillary lymph node metastasis in SLNs 
by using color Doppler US and CEUS with Sonazoid 
administering intravenously
Three breast surgeons (F.M., T.E., T.S.) and ultrasonog-
raphers performed US of axilla as written bellow. Lymph 
nodes were categorized as positive metastasis if they 
exhibited more than two number of vascularities except 
for the place of hilum.
Histopathological examinations
Post operatively, all slices were fixed in 10  % buffered 
formalin, embedded in paraffin, and microscopically 
examined using hematoxylin and eosin staining. Hema-
toxylin-eosin stained tumor deposits not larger than 
2 mm were defined as micrometastasis.
Statistical analysis
We calculated the sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), and accu-
racy (ACC) for color Doppler US, CECT and CEUS with 
Sonazoid comparing the imaging findings with pathologi-
cal results. We used χ2 test or Fisher exact test to determine 
the correlation among these results. All differences were 
considered significant P < 0.05. All statistical analysis were 
performed using JMP pro 11 software (SAS Institute Japan).
Conclusion
This study revealed that the evaluation of axillary SLN 
detection using CEUS with Sonaziod administering sub-
areolarly and the evaluation of metastasis in SLNs using 
CEUS with Sonazoid administering intravenously is 
the most accurate in those using other modalities, the 
accuracy reached over 90  %. CEUS with Sonazoid can 
evaluate microvessels, and that is the cause of improved 
results. Although more experiences are needed for fur-
ther improvement of accurate diagnosis, the evaluation 
of axillary SLN metastasis using combination of CEUS 
with Sonazoid administering both subareolarly and intra-
venously would take the place of conventional sentinel 
lymph node biopsy in breast cancer surgery.
Abbreviations
SLNB: sentinel lymph node biopsy; SLNs: sentinel lymph nodes; ALND: axillary 
lymph node dissection; ALNs: axillary lymph nodes; CEUS: contrast enhanced 
ultrasonography; US: ultrasonography; CECT: contrast enhanced computed 
tomography; MIs: mechanical indices; PPV: positive predictive value; NPV: 
negative predictive value; ACC: accuracy; cMRI: contrast-enhanced magnetic 
resonance imaging; PET: fluoro-2-deoxy-d-glucose-positron emission 
tomography.
Fig. 3 An Axillary lymph node detection using contrast-enhanced 
ultrasonography with Sonazoid injected subareolarly. A single route/
single SLN pattern in a 64-year-old woman with 18 × 17-mm tumor 
in the left lower outer quadrant area, where only a single common 
lymph vessel from the subareolar area (white arrow head) drains into a 
single common SLN (white arrow)
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